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G6PD deﬁ ciency: a polymorphism balanced by heterozygote 
advantage against malaria
Very few people would doubt nowadays that Darwinian 
selection pervades not only the macroevolution of 
organisms, but also the microevolution of the human 
species. As a convincing example, many biology 
teachers, and certainly most haematologists, will 
choose sickle cell and malaria, and the reason is clear. 
Homozygous sickle cell anaemia (SS) is a serious 
inherited (autosomal recessive) disease that, left 
untreated, reduces life expectancy greatly; therefore, 
AS heterozygotes must have a remarkable advantage to 
balance the loss of homozygotes and enable this genetic 
polymorphism to persist. Indeed, almost every one of 
innumerable studies have shown that malaria parasite 
counts, the occurrence of severe malaria, and death 
from malaria are all signiﬁ cantly lower in individuals 
who are AS heterozygotes than in those without the 
sickle cell allele (AA controls).
Considering that Plasmodium falciparum is viciously 
pathogenic, one can envisage several other genes in 
which variant alleles might be protective (eg, those 
that aﬀ ect the immune response or those that aﬀ ect 
adhesion of parasites to small vessels in the brain). 
Because the pathogenic eﬀ ects of P falciparum are 
exerted through the intraerythrocytic cycle, polymorphic 
genes expressed in red blood cells should be prime 
candidates. This notion was ﬁ rst clearly formulated 
by J B S Haldane in 1949; and with respect to glucose 
6-phosphate dehydrogenase (G6PD) deﬁ ciency, it was 
pioneered by A C Allison and A G Motulsky in 1960. In 
the Lancet Haematology, Sophie Uyoga and colleagues 
present a new important study on this topic,1 based on 
clinical work done in Kenya. 
G6PD deﬁ ciency diﬀ ers from sickle cell anaemia in 
many ways; of which at least two are highly pertinent 
to malaria selection. First, G6PD deﬁ ciency is not on 
its own a generally serious disease: on the contrary, 
G6PD deﬁ ciency is mostly asymptomatic, although it 
does predispose to severe neonatal jaundice, and to 
acute haemolytic anaemia after exposure to exogenous 
agents such as infection, fava beans, and some drugs.2 
Second, the G6PD gene maps to the X chromosome. 
Therefore, there is only one allele in males (it will 
produce either normal G6PD or G6PD deﬁ ciency), but 
two alleles in females. If one allele is normal and the 
other is a mutant—ie, if a female is a heterozygote 
for an X-linked gene such as G6PD—X chromosome 
inactivation (lyonisation) will produce somatic cell 
mosaicism.3 In samples from mosaic heterozygotes, 
cytochemical staining has shown that P falciparum was 
more prevalent in G6PD normal red blood cells than in 
G6PD deﬁ cient red blood cells.4 
Subsequently, several clinical ﬁ eld studies done both 
in west Africa and in east Africa have shown consistently 
that severe malaria is rarer in children with G6PD 
deﬁ ciency than in children without the deﬁ ciency and 
that they have lower levels of parasitaemia. However, 
the questions of which genotypes are protective 
has been controversial; particularly since a paper in 
Nature5, in which protection was claimed for both 
hemizygous males and heterozygous females. In that 
study—it is now clear—many children with G6PD 
deﬁ ciency were misclassiﬁ ed as normal. The report by 
Uyoga and colleagues1 has the strength of including 
many participants from a centre with great expertise 
in malaria research; in addition, they showed that 
heterozygotes have not only less severe malaria, but also 
decreased mortality. I felt gratiﬁ ed that both this paper 
and the recent multicentre study by the MalariaGen 
consortium6 vindicated our claim of more than 40 years 
ago, that the key to protection from P falciparum are the 
girls heterozygous for G6PD deﬁ ciency.7   
From the point of view of haematology, at least 
two further points deserve mention. First, Uyoga and 
colleagues1 found that boys with G6PD deﬁ ciency were 
not only unprotected from severe malaria, but also 
that they seem to be at greater risk of malaria with 
severe anaemia, possibly because their G6PD deﬁ cient 
red blood cells suﬀ er oxidative damage. Second, the 
retention of 12% of enzyme activity (a loss of 88%) 
in G6PD deﬁ cient hemizygous boys and homozygous 
girls should not engender complacency. These patients 
are at risk of drug-induced acute haemolytic anaemia.8 
Although a dapsone-containing anti-malarial drug 
has been taken oﬀ  the market,9 researchers and 
medical workers must be aware of a resurgence in the 
use of primaquine, the only drug that can eliminate 
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P falciparum gametocytes, for which only a single low 
dose is required. It is also the only drug that can eﬀ ect 
radical therapy of Plasmodium vivax, for which multiple 
doses are needed, which would cause haemolysis in 
people with G6PD deﬁ ciency. It has been accepted, at 
long last, that a test for G6PD deﬁ ciency ought to be 
carried out in these cases before prescribing primaquine. 
The cellular mechanism of protection in heterozygotes 
is not yet fully elucidated. It is not surprising that 
investigating malaria selection has proven more diﬃ  cult 
for G6PD than for haemoglobin S. The advantage 
to haemoglobin S heterozygotes is strong (and 
persisting), whereas most G6PD deﬁ cient individuals 
are asymptomatic in the steady state, and the only 
cause of pre-reproductive mortality (before drugs were 
introduced) was probably severe neonatal jaundice 
in a minority of newborn babies.2 Therefore, a lesser 
advantage against P falciparum is needed to achieve 
balance. Polymorphism for an X-linked gene can reach 
stability only when heterozygotes have the greatest 
ﬁ tness:10 G6PD deﬁ ciency in malaria-endemic regions is 
a textbook example in human populations. 
Lucio Luzzatto
Deptartment of Haematology, Muhimbili University Hospital, Dar 
es Salaam, Tanzania; and Istituto Toscano Tumori, Florence, Italy
lucio.luzzatto@ittumori.it  
I declare no competing interests.  
Copyright © Luzzatto. Open Access article distributed under the terms of 
CC BY-NC-SA. 
 1 Uyoga S. Glucose-6-phosphate dehydrogenase deﬁ ciency and the risk of 
malaria and other diseases in children on the coast of Kenya: a case-control 
and a cohort study. Lancet Haematology 2015; published online Sept 23. 
http://dx.doi.org/10.1016/S2352-3026(15)00152-0
 2 Luzzatto L, Poggi VE. Glucose 6-phosphate dehydrogenase deﬁ ciency. 
In: Orkin SH, Nathan, DG, Ginsburg D, Look, TA, Fisher DE, Lux SE, eds. 
Hematology of infancy and childhood. Philadelphia: Saunders; 
2009. 883–907.
 3 Beutler E, Yeh M, Fairbanks VF. The normal human female as a mosaic of 
X-chromosome activity: studies using the gene for G6PD deﬁ ciency as a 
marker. Proc Natl Acad Sci USA 1962; 48: 9–16.
 4 Luzzatto L, Usanga EA, Reddy S. Glucose 6-phosphate dehydrogenase 
deﬁ cient red cells: resistance to infection by malarial parasites. Science 
1969; 164: 839–42.
 5 Ruwende C, Khoo SC, Snow RW, et al. Natural selection of hemi- and 
heterozygotes for G6PD deﬁ ciency in Africa by resistance to severe malaria. 
Nature 1995; 376: 246–49.
 6 Malaria Genomic Epidemiology Network. Reappraisal of known malaria 
resistance loci in a large multicenter study. Nat Genet 2014; 46: 1197–204.
 7 Bienzle U, Ayeni O, Lucas AO, Luzzatto L. Glucose-6-phosphate 
dehydrogenase deﬁ ciency and malaria. Greater resistance of females 
heterozygous for enzyme deﬁ ciency and of males with non-deﬁ cient 
variant. Lancet 1972; 299: 107–10.
 8 Pamba A, Richardson ND, Carter N, et al. Clinical spectrum and severity of 
hemolytic anemia in glucose 6-phosphate dehydrogenase-deﬁ cient 
children receiving dapsone. Blood 2012; 120: 4123–33.
 9 Luzzatto L. The rise and fall of the antimalarial Lapdap: a lesson in 
pharmacogenetics. Lancet 2010; 376: 739–41.
 10 Kirkman HN. Properties of X-linked alleles during selection. Am J Hum Genet 
1966; 18: 424–32.
